The aim of this study was to investigate the in vitro immunomodulatory effects of zoledronic acid (Zol) on peripheral blood Vc9/Vd2 (cd) T cells of normal donors and multiple myeloma (MM) patients. cd T cells were stimulated with Zol and low doses of interleukin-2 (IL-2), and then analyzed for proliferation, cytokine production, and generation of effector activity against myeloma cell lines and primary myeloma cells. Proliferation of cd T cells was observed in 100% of normal donors and 50% of MM patients. cd T cells produced IFN-c, surface mobilized the CD107a and CD107b antigens, and exerted direct cell-to-cell antimyeloma activity irrespective of the ability to proliferate to Zol and IL-2. The memory phenotype was predominant in the MM cd T cells that proliferated in response to Zol (responders), whereas effector cells were predominant in those that did not (nonresponders). Zol induced antimyeloma activity through the monocyte-dependent activation of cd T cells and by enhancing the immunosensitivity of myeloma cells to cd T cells. Mevastatin, a specific inhibitor of hydroxy-methylglutaryl-CoA reductase, completely abrogated this antimyeloma activity.
Introduction
Multiple myeloma (MM) remains incurable by conventional or high-dose chemotherapy. Residual tumor cells uniformly survive chemotherapy and are responsible for clinical relapse. Idiotype vaccines delivered after high-dose chemotherapy can generate long-lasting and tumor-specific immune responses, but do not eliminate the residual tumor burden. [1] [2] [3] There is in vitro evidence that T cells recognize myeloma cells and generate antimyeloma activity. [4] [5] [6] Both T cells and dendritic cells, however, have been shown to be functionally defective. [7] [8] [9] [10] [11] This may explain why active specific immunotherapy has fallen short of clinical expectations.
The role of innate effector cells such as macrophages, NK cells, NKT cells, and gd T cells in natural tumor immunity and tumor immunotherapy has recently been revisited. 12, 13 Circulating gd T cells constitute about 1-5% of peripheral blood T cells. More than 70% of them use the same T-cell receptor (TCR) V region pair Vg9-Vd2 and express the CD3 þ CD4À CD8À phenotype.
14 This TCR enables them to recognize families of unprocessed nonpeptide compounds of low molecular weight (100-600 Da) with conserved patterns including microbial metabolites such as pyrophosphomonoesters and alkyl amines. 15, 16 Certain hemopoietic tumor cell lines, such as the Daudi Burkitt's lymphoma and the RPMI 8226 myeloma line are also recognized and lysed by gd T cells in vitro. 17, 18 Aminobisphosphonates (NBPs) are a new class of drugs commonly used in MM and other cancer patients to prevent effectively osteoclast activation and related skeletal events. They share the chemical features of nonpeptide compounds naturally recognized by gd T cells. It has been proposed that the ability to activate gd T cells may contribute to the clinical efficacy of NBPs in MM. 19, 20 However, MM cells from about 50% of patients inexplicably fail to react to in vitro stimulation with NBPs, 19, 21 and it has been assumed that these patients cannot benefit from the immunomodulatory properties of NBPs. 21 Zoledronic acid (Zol) is the most potent NBP clinically available. In normal donors, it displays a more potent ability to expand and activate gd T cells, 22 whereas no data have been reported for MM patients. The aim of this work was to investigate the immunomodulatory properties of Zol in MM patients, especially those whose gd T cells do not react to NBPs in vitro.
Materials and methods

Patients
In all, 52 MM patients entered this study after informed consent from January 2002 to January 2004. In total, 26 patients were evaluated at diagnosis; 26 were on first-or second-line chemotherapy according to the Italian Myeloma Study Group protocols. All patients receiving treatment were studied at least 3 weeks after the last day of chemotherapy. The control group consisted of 52 age-matched normal donors kindly provided by the local blood bank after informed consent.
Culture conditions
Peripheral blood mononuclear cells (PBMCs) were purified by centrifugation on a Ficoll-Hypaque density gradient. Bone marrow mononuclear cells (BMMCs) were obtained after passing bone marrow aspirates through needles of decreasing gauge, and incubation with red cell lysis buffer.
PBMCs or BMMCs were cultured for the indicated time at 1 Â 10 6 /ml in flat-bottomed microtiter plates at 371C in a humidified atmosphere of 5% CO 2 in air. The standard culture medium was RPMI 1640 (Eurobio, Les Ulis, France), containing 10% fetal calf serum (FCS) (Mascia Brunelli, Milan, Italy), 2 mM L-glutamine (Eurobio, Les Ulis, France), 100 U/ml penicillin (Eurobio, Les Ulis, France), and 100 mg/ml streptomycin (Eurobio, Les Ulis, France). Culture conditions were: medium alone, interleukin-2 (IL-2) (Eurocetus, Milan, Italy) at 10 IU/ml final concentration, Zol at 1 mM final concentration (kindly provided by Novartis Pharma, Origgio, Italy), and Zol 1 mM þ IL-2 10 IU/ml.
In selected experiments, monocytes, gd T cells, or plasma cells were removed by positive immunomagnetic sorting, using CD14, phycoerythrin (PE)-conjugated anti TCRgd mAb plus anti-PE MicroBeads, or CD138 antibodies and MiniMACS columns (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
The KMM1 and KMS11 myeloma cell lines (kindly provided by Dr Leif Bergsagel) were used in coculture experiments. Cell lines were mycoplasma free after screening with PCR assay. In selected experiments, cell lines were incubated with IL-2 10 IU/ ml, Zol 1 mM, or 25 mM Mevastatin (Mev) (Sigma-Aldrich, Milan, Italy), alone or in combination, and left untreated or further incubated with PBMCs as indicated in the Results.
Flow cytometry
Immunophenotyping was performed with the following mAbs: anti-CD3 (Caltag Laboratories, Burlingame, CA, USA); anti-CD16, anti-TCR ab (Pharmingen, San Diego, CA, USA); antipan-TCR gd (Endogen, Woburn, MA, USA); anti-CD3, anti-pan-TCR gd, anti-TCRVg9, anti-CD56 (Becton Dickinson, San José, CA, USA); anti-CD14, anti-CD4, anti-CD8 (Dako, Glostrup, Denmark); anti-CD27 (Alexis, Lausen, Switzerland); anti-CD45RA (Caltag Laboratories, Burlingame, CA, USA), and anti-CD107a and -CD107b (Pharmingen, San Diego, CA, USA). Appropriate combinations of fluorescein isothiocyanate (FITC)-, PE-, Tri color (TC)-, or allophycocyanin-conjugated mAbs were used.
Flow cytometry was performed with a FACScan cell sorter and CELLQuest software (Becton Dickinson, Mountain View, CA, USA). Total counts of specific cell subsets per well were determined by multiplying total counts of viable cells per well by the percentage of cells of interest, as identified by two-or three-color flow cytometry and appropriate gating on morphology and propidium iodide (PI) (Sigma-Aldrich, Milan, Italy) staining.
Myeloma cells were identified by cell surface staining with PE-conjugated anti-CD38 mAb (Becton Dickinson, San José, CA, USA) and intracellular staining with FITC-conjugated goat anti-human k or l light chains (Biosource International, Camarillo, CA, USA). Membrane permeabilization was performed using Fix and Perm reagent (Caltag Laboratories, Burlingame, CA, USA). In selected experiments, myeloma cells were identified by carboxy-fluorescein diacetate succinimidyl ester (CFSE) labeling (Molecular Probes, Eugene, OR, USA), according to the manufacturer's instructions.
Proliferation assays
Freshly isolated PBMCs were labeled with 5 mM CFSE, washed once, and stimulated with the appropriate reagents. On day 7, cells were surface stained with anti-TCRgd mAb and proliferation was determined by evaluating the logarithmic decrease of CFSE fluorescence intensity after gating on gd T cells.
Cytokine quantification
Both intracellular and extracellular cytokine production were assessed. In total, 1 Â 10 6 PBMCs were incubated with PHA 2 mg/ml (Sigma-Aldrich, Milan, Italy), PMA 10 ng/ml (SigmaAldrich), ionomycin 500 ng/ml (Sigma-Aldrich), and monensin 2 mM (Sigma-Aldrich) for 4 h at 371C and 5% CO 2 . Cells were washed with staining buffer (phosphate-buffered saline supplemented with 1% FCS and 0.1% sodium azide) and incubated for 30 min at 41C with TC-conjugated anti-CD3 and PE-or FITCconjugated anti-TCRgd. After extensive washing, cells were fixed with 4% p-formaldehyde for 20 min at room temperature, washed twice with permeabilization buffer (0.1% saponin in staining buffer), and incubated with FITC-conjugated anti-IFN-g (Pharmingen, San Diego, CA, USA) or PE-conjugated anti-IL-4 (Pharmingen, San Diego, CA, USA). FITC-and PE-conjugated isotype-matched mouse immunoglobulins were used as controls. Intracellular cytokine staining was evaluated by two-or three-color flow cytometry. The cytokine contents of Zolstimulated gd T-cell supernatants were assessed with the quantitative FlowCytomix multiple cytokine detection kit (Bender MedSystem, Vienna, Austria), according to manufacturer's instructions.
Antimyeloma activity of Zol-activated gd T cells
In the first set of experiments, cultures were initiated with PBMCs in the presence of the appropriate reagents as described above. On day 1, KMM1 cells were added to PBMCs at 10% final dilution and viable counts of myeloma cells were scored on day 5. In the second set, PBMCs were split on day 6 into different aliquots, which were further processed according to the experimental protocol. Based on cell number availability, one aliquot was left untreated, one was transferred into the bottom half of Transwell plates, one was depleted of gd T cells by immunomagnetic cell sorting, and one was incubated with antigd or anti-ab TCR mAbs without further processing; KMM1 or KMS11 myeloma cells were added to the aliquots and scored 18 h later by multiplying total counts of viable cells per well by the percentage of myeloma cells, as identified by cytoplasmic staining of the appropriate tumor-specific immunoglobulin lightchain antibody. To confirm the antimyeloma activity of Zolactivated gd T cells, we also used a new flow cytometric assay based on CFSE staining of target cells and identification of dead cells by PI staining of CFSE-labeled target cells. 23 This method works as a single-platform assay and does not require cell counting to determine the percentage of killed cells in each well. In these experiments, PBMC were incubated with fixed numbers of CFSE-labeled KMM1 cells at different effector-totarget cell ratios (as in the conventional 51 Cr release assay), or decreasing numbers were incubated with increasing numbers of CFSE-labeled KMM1 cells to simulate the varying degree of myeloma cell bone marrow infiltration in vivo.
Experiments were also performed with primary myeloma cells using BMMCs from five MM patients and PBMCs from a patient with plasma cell leukemia. In four experiments, cells were left untreated or supplemented on day 1 with Zol þ IL-2 or IL-2 alone. Residual myeloma cells were scored on day 7 as described above. In two experiments, BMMCs were depleted of CD138 þ cells by positive selection. Decreasing numbers of BMMCs CD138À were then reconstituted with increasing numbers of purified CFSE-labeled CD138 þ cells to give a final percentage of CD138 þ cells per well from 5 to 60%. Cultures were stimulated with Zol þ IL-2 or IL-2 alone, and the percentage of dead CD138 þ cells (CFSE þ PI þ ) was determined on day 7 by flow cytometry.
In selected experiments, KMM1 or KMS11 myeloma cells were pretreated for 18 h with 1 mM Zol, 25 mM Mev, or their combination and extensively washed before mixing with treated or untreated PBMCs.
Lastly, KMM1 and KMS11 cells, untreated or treated with 1 mM Zol, 25 mM Mev, or their combination were cultured up to 5 days in medium alone, IL-2, or Zol þ IL-2 to determine any direct effect of these stimuli on their growth rate and/or viability.
Statistical analysis
Results were expressed as mean7s.e. Differences between sample groups were evaluated with the two-tailed nonparametric Mann-Whitney U-test for unpaired or paired samples or with Fisher's exact test for unpaired data. Po0.05 was considered significant.
Results and discussion
Selective expansion of gd T cells by Zol þ IL-2
Based on preliminary results, 1 mM Zol and 10 U/ml IL-2 were selected as the standard culture conditions. Figure 1a shows total counts of viable gd T cells in normal donors and MM patients after incubation for 7 days with the different stimuli. The largest expansion of gd T cells was observed after stimulation with Zol þ IL-2 in both normal donors and MMs (always Po0.05 compared with medium, IL-2 alone, and Zol alone). The supravital CFSE staining assay confirmed that active proliferation was the main cause of gd T-cell expansion (data not shown). An increase was also observed in normal donors after stimulation with Zol alone (always Po0.05 compared to medium and IL-2 alone) but not in MM. IL-2 alone did not induce any significant expansion of gd T cells.
Unlike gd T cells, total counts of ab T cells, monocytes (CD14 þ ), and B cells (CD19 þ ) were unaffected by stimulation with IL-2, Zol, or their combination. NK cells (CD56 þ CD3À) were slightly increased compared with medium alone when IL-2 was present in normal donors and MM cultures. Almost all gd T cells expressed the Vg9 segment, and about 50% were CD4-and CD8-in both normal donors and MM (data not shown).
Proliferative responses to Zol þ IL-2 differentiate two subsets of MM patients Normal donors showed significantly higher gd T-cell counts than MM patients after stimulation with Zol þ IL-2 (106 000715 700/ well vs 67 300727 800/well, Po0.005) (see also Figure 1a ). This reflected the presence of two subsets of patients with very different proliferative responses to Zol þ IL-2. Out of 52 MM patients, 25 showed total counts of gd T cells after stimulation in the same range as normal donors and were defined as responders (R), whereas the values of the other 27 were below the mean þ 3 s.d. of values after stimulation and were defined as non-responders (NR). A representative R and NR patient are shown in Figure 1 (panels b and c). Kunzmann et al have also shown that pamidronate and IL-2 do not expand gd T cells in 42 and 54% of MM patients when experiments are performed with BMMCs 19 and PBMCs, 21 respectively. In the five experiments in which PBMCs were depleted of CD14 þ cells and compared head-to-head with unmanipulated PBMCs, this depletion hampered the expansion of gd T cells induced by Zol þ IL-2 stimulation (63 000718 000/well vs 17 90079000, P ¼ 0.03). Thus, the proliferative expansion of gd T cells in MM was dependent on monocytes, as previously reported for pamidronate. 24 However, baseline mean values of monocytes were similar in normal donors, R, and NR patients at the initiation of the cultures.
Different distribution of memory and effector gd T-cell subsets in R and NR patients
gd T cells can be divided into subsets according to their phenotype, proliferative capacity, and effector functions. Naive and memory gd T cells (both CD27 þ ) display high proliferative capacity, but low effector functions, whereas effector and late effector gd T cells (both CD27À) display the opposite pattern.
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CD27 þ gd T cells were the major subset in R (Figure 2a) , whereas CD27À gd T cells predominated in NR patients (Figure 2b ). Further analysis showed that the major subset in R consisted of memory cells (CD45RAÀ CD27 þ ), with the highest proliferative capacity among gd T cells. 25 On the contrary, the major subset in NR consisted of late effector cells (CD45RA þ CD27À), which have the highest effector activity. 25 A representative R and NR patient are shown in Figure 2 , (panels c and d). The small proportion of naive/memory cells may explain why NR did not mount a proliferative response after stimulation with Zol and IL-2.
Both R and NR gd T cells are functionally activated by Zol
After stimulation for 7 days with Zol þ IL-2, IFN-g production at the intracellular level was detected in 5271%, 60711%, and Stimulation of gd T cells by Zol. In panel a, PBMCs from normal donors and MM patients were incubated for 7 days in medium, 10 IU/ml IL-2, 1 mM Zol, or 1 mM Zol þ 10 IU/ml IL-2. Results are expressed as total counts per well of viable gd T cells. Each bar represents the mean value7s.e. from seven to 13 experiments in normal donors and from 11 to 20 experiments in MM. Cytofluorometric analyses of a representative R and NR patient after 7 days stimulation with Zol and IL-2 are shown in panels b and panel c, respectively.
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S Mariani et al 4173% of gd T cells from two R, four NR patients, and four normal donors respectively, whereas IL-4 production was never observed. IFN-g was also increased in the supernatants of gd T cells of three R, four NR patients, and three normal donors after stimulation with Zol þ IL-2-vs IL-2 alone, whereas IL-4, IL-5, and IL-10 levels were unchanged. The net increase (200 pg/ml) was similar in all groups, although the absolute concentration of IFN-g per well was five-fold higher in R, and three-fold higher in normal donors than NR. This reflected the different proliferation rate and total counts of gd T cells at the end of the cultures. This, in turn, reflects the different subset distribution and functional properties of gd T cells in R and NR. In particular, late effector cells (CD45RA þ CD27À) are highly represented in NR patients and produce low amounts of IFN-g, even if they have strong TCR-mediated effector activity (see below, and Angelini et al 26 ) . To further characterize the cytolytic capability of gd T cells of R and NR, we investigated the surface mobilization of CD107a and CD107b after Zol þ IL-2 stimulation. CD107a and CD107b are integral membrane proteins located in cytolytic granules that become transiently mobilized to the cell surface during degranulation. 27, 28 The former was investigated in four R and five NR, whereas the latter in one R only. The increase of expression vs IL-2 alone (1.5-fold) and the percent of CD107a/ b þ gd T cells were similar in PBMCs of R and NR (39713 vs 2276%, P40.05) after stimulation with Zol þ IL-2. These data as a whole indicate that Zol activates the effector functions of gd T cells in both R and NR patients.
Both R and NR Zol-activated gd T cells inhibit the growth of myeloma cells
Next, we asked whether Zol-activated gd T cells had similar antimyeloma activity. PBMCs from R and NR were incubated with KMM1 cells from day 1 to 5 with Zol þ IL-2 or IL-2 alone as a control. On day 5, the proliferative expansion of gd T cells in R had not yet occurred. KMM1 cell growth was strongly inhibited in both R and NR (Figure 3a) , whereas gd T cells were significantly expanded on day 7 in R only (Figure 3b) . A similar dissociation between proliferation and activation of effector functions has been reported in SCID mice reconstituted with human PBMCs after infection with Gram þ or GramÀ bacteria, 29 and in a mouse model in which antibacterial effects against Escherichia Coli occurred irrespective of gd T-cell expansion. 30 These data indicate that the effector functions of gd T cells can be induced independently from their proliferation, a common feature among effectors of innate immunity.
Zol-induced antimyeloma activity is dependent on direct cell-to-cell contact
To investigate the reciprocal role of direct cell-to-cell contact vs IFN-g in Zol-induced antimyeloma activity, PBMCs from one R and three NR were cultured from day 6 to 7 in the bottom half of Transwell culture plates with KMM1 cells in the top half (10% final concentration). No antimyeloma activity was detected in the Transwell plates, whereas it was 41 and 4473% in plates in which the R and NR PBMCs were cocultured with KMM1 cells. Thus, direct cell-to-cell contact is the main mechanism by which Zol-activated gd T cells act on myeloma cells, whereas soluble factors such as IFN-g are not involved. This finding also explains why Zol-activated gd T cells have similar antimyeloma activity despite the five-fold higher concentration of IFN-g in the supernatants of R vs NR after 7 days stimulation with Zol þ IL-2 (see above).
To prove that gd T cells were indeed responsible for the Zolinduced antimyeloma activity, PBMCs from four R and one NR were depleted of gd T cells immediately before the addition of KMM1 cells. Removal of gd T cells completely abrogated the antimyeloma activity induced by Zol and IL-2 ( Figure 3c ). Flow cytometry of residual gd T cells showed that the TCR was still engaged by the mAb used for their removal. To determine whether the blockade of gd TCR was sufficient to prevent antimyeloma activity and was specific, two experiments were performed in which PBMCs were left untreated, or incubated with anti-gd TCR or anti-ab TCR without subsequent depletion of mAb-coated cells. Antimyeloma activity was unaffected by antiab TCR treatment, whereas it was completely abrogated by antigd TCR treatment (data not shown). Altogether, these data provide direct evidence that gd T cells exert antimyeloma activity through cell-to-cell contact and gd TCR engagement, as recently reported by Kabelitz et al.
31
Zol-activated gd T cells exert antitumor activity against primary myeloma cells
BMMCs from two R (containing 10 and 19% myeloma cells, respectively) and one NR patient (containing 55% myeloma cells) at diagnosis, and PBMCs from one R with plasma cell leukemia (containing 16% circulating myeloma cells) were incubated with Zol þ IL-2 or with IL-2 alone as a control. On day 7, the mean inhibition of myeloma cell survival was Immunomodulation of zoledronic acid in human myeloma S Mariani et al 5674% with Zol and IL-2 compared with IL-2 alone. These data indicate that, whatever the cell surface molecules targeted by Zol-activated gd T cells, they are also expressed by primary myeloma cells other than myeloma cell lines. As shown for myeloma cell lines, a depletion experiment confirmed that Zolinduced antitumor activity was strictly dependent on gd T cells (data not shown).
Range of efficacy of Zol-activated gd T cells
This series of experiments was performed to explore the magnitude of the tumor burden against which Zol-activated gd T cells were able to exert antimyeloma activity. Decreasing numbers of PBMCs or CD138-depleted BMMCs were incubated with increasing numbers of KMM1 cells, or purified autologous CD138 þ cells, to simulate the varying degree of myeloma cell bone marrow infiltration in vivo. CFSE-labeled KMM1 or CD138 þ cells were used as target cells. The most effective antimyeloma activity, compared with IL-2 alone, was observed when the proportion of target cells ranged from 5% (myeloma cell killing: R, 6077%; NR, 5074%) to 40% (R; 2877%; NR 2072%). Above this percentage, the antitumor efficiency of Zol-activated gd T cells declined and slightly faster in NR than R. These data support the view that activation of innate effector mechanisms could be particularly useful against minimal residual disease. 12 Zol enhances the sensitivity of myeloma cells to the effector functions of gd T cells It has been shown that tumor cell lines become more susceptible to gd T-cell-mediated cytotoxicity after a brief pulsing with NBPs. 32, 33 We therefore determined whether a direct effect on myeloma cells contributed to the antitumor activity induced by Zol. KMM1 myeloma cells were pretreated with Zol for 18 h before mixing with R or NR PBMCs and coculturing for 4 days in the presence of IL-2 only. PBMCs incubated with IL-2 and untreated KMM1 cells served as the controls. The growth of Zoltreated myeloma cells was strongly inhibited in both R and NR (Figure 4a) , and gd T cells were still expanded on day 7 only in R (Figure 4b ). These results indicate that short-term incubation with Zol confers the following properties on KMM1 cells: (1) the ability to induce the proliferative expansion of gd T cells, but only in R; (2) a higher susceptibility to the effector mechanisms of gd T cells in both R and NR.
Antimyeloma activity induced by Zol is mediated by the mevalonate pathway
Two nonmutually exclusive interpretations have been proposed to explain the enhanced immunosensitivity of tumor cells after exposure to NBPs: (1) NBPs bind to the tumor cell surface and directly target the effector functions of gd T cells; 32 (2) NBPs are internalized by tumor cells and indirectly enhance their immunosensitivity to gd T cells by modulating the mevalonate pathway. 33 Interestingly, it has been proposed that some tumor cells may have an innate susceptibility to gd T-cell recognition because they accumulate phosphorylated mevalonate metabolites that are similar to the phosphorylated nonpeptidic ligands of gd T cells. 33 This accumulation is due to the increased expression of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate-limiting enzyme in the mevalonate pathway. Zol is a very potent inhibitor of farnesyl-pyrophosphate synthase (FPP), an enzyme acting downstream from HMGR in the mevalonate pathway. 34 One can predict that Zol-treated tumor cells are more susceptible to gd T cells because they accumulate the phosphorylated mevalonate metabolites by means of two mechanisms: inhibition of FPP and increased expression of HMGR. Based on this model, one can also predict that inhibition of HMGR will abrogate the susceptibility to gd T cells because the metabolites are not accumulated and FPP inhibition has no effect. To determine the role of this pathway in the immunomodulatory activity of Zol, KMM1 or KMS11 cells were pretreated with Zol in the presence of Mev, a specific HMGR inhibitor, before mixing with PBMCs and IL-2. The growth inhibition of Zol-pretreated myeloma cells was completely reverted by Mev, which slightly increased their proliferation rate as compared with IL-2 alone (Figure 4c ). These data indicate that the effects determined by Zol on 
Conclusions
Our data indicate that: (1) Zol activates the effector functions of gd T cells in both R and NR; (2) Zol-induced antitumor activity is dependent on direct cell-to-cell contact; (3) R and NR have distinct distributions of naive, memory, and effector gd T cells; (4) both gd T cells and myeloma cells are targeted by Zol; (5) the effects of Zol on gd T cells and myeloma cells are dependent on the mevalonate pathway.
